Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Eli Lilly and Company(NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active…

View More Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

PFIZER ANNOUNCES PHASE 3 TOP-LINE RESULTS FOR RIVIPANSEL IN PATIENTS WITH SICKLE CELL DISEASE EXPERIENCING A VASO-OCCLUSIVE CRISIS

Pfizer Inc. (NYSE:PFE) announced  that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints.…

View More PFIZER ANNOUNCES PHASE 3 TOP-LINE RESULTS FOR RIVIPANSEL IN PATIENTS WITH SICKLE CELL DISEASE EXPERIENCING A VASO-OCCLUSIVE CRISIS

FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved RECARBRIO™ (imipenem, cilastatin,…

View More FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available